Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies
EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives
EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
Now Viewing
EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
Video content above is prompted by the following question:
- What are your final thoughts regarding unmet needs and future perspectives for CAR T-cell therapy in relapsed/refractory multiple myeloma?
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
